期刊
CURRENT DRUG TARGETS
卷 7, 期 8, 页码 975-992出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945006778019381
关键词
tachykinin; antagonist; clinical development; medicinal chemistry; emesis; irritable bowel syndrome; schizophrenia
In this chapter it is described how, starting from different approaches and through extensive medicinal chemistry studies, several discovery compounds were optimized and reached the development stage. The first tachykinin receptor antagonist to reach the market in 2003 for chemotherapy-induced emesis has been aprepitant. Other clinical candidates (for central nervous system disorders: osanetant, talnetant and saredutant: for irritable bowel syndrome: nepadutant and saredutant) are in advanced clinical phase. The clinical studies reported in the literature and the destiny of the clinical candidates, where available. will be reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据